BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide β a chain of 15 amino acids β derived from a partial sequence of a protective protein naturally found in human gastric juice. First isolated and characterised in gastric research during the 1990s, BPC-157 has since become one of the most extensively studied peptides in tissue-repair and regenerative research, appearing in preclinical literature spanning tendon and ligament healing, angiogenesis, gastrointestinal protection, and nerve regeneration models. Its stability, broad tissue tropism, and apparent activity across multiple healing pathways distinguish it from more narrowly-targeted research peptides.
Origin and Structural Characteristics
BPC-157 is derived from BPC (Body Protection Compound), a protein identified in human gastric juice that appears to play a protective role in maintaining the integrity of the gastrointestinal mucosa. Unlike many therapeutic peptides, BPC-157 demonstrates unusual stability in gastric fluid β research has recorded biological activity even after oral administration in rodent models, an uncommon property for a peptide of its size. This stability profile, combined with a lack of a defined toxic dose observed across multiple studies, has made it a peptide of considerable interest for researchers working across several unrelated tissue-repair models simultaneously.
Mechanism of Action
BPC-157's research profile spans several interconnected biological pathways. No single receptor has been definitively established as its primary target, and current literature points to a multi-modal mechanism:
Angiogenesis via VEGFR2 Signalling
A substantial body of preclinical research has focused on BPC-157's pro-angiogenic activity β its capacity to stimulate the formation of new blood vessels. Studies using chorioallantoic membrane assays and rodent models have shown BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) expression and promotes endothelial cell migration, a mechanism believed to underlie its effects on wound healing and tissue perfusion in damaged tissue models.
Nitric Oxide Pathway Modulation
Research has also implicated the nitric oxide (NO) system in BPC-157's activity profile. Studies in rodent models suggest BPC-157 interacts with the NO system in a way that supports vascular tone regulation and may contribute to its protective effects in models of organ ischemia, including studies of gastrointestinal, hepatic, and cardiac tissue under experimentally induced ischemic stress.
Growth Factor and Cytokine Modulation
Additional preclinical studies have reported that BPC-157 influences the expression of growth factors involved in tissue remodelling, including early growth response protein 1 (EGR-1) and transforming growth factor beta (TGF-Ξ²), alongside modulation of pro-inflammatory cytokine activity at sites of induced tissue injury.
Preclinical Research Applications
Across published preclinical literature, BPC-157 has been studied in several distinct tissue-repair contexts:
- Tendon-to-bone healing: Rodent studies of surgically transected Achilles tendons and ligament-to-bone models have reported accelerated healing and improved biomechanical strength in BPC-157-treated groups compared to controls.
- Gastrointestinal protection and healing: A significant portion of the foundational literature examines BPC-157 in models of gastric ulceration, inflammatory bowel disease, and fistula healing, consistent with its gastric-derived origin.
- Muscle injury research: Studies of crush and laceration injury models in skeletal muscle have reported accelerated functional recovery associated with BPC-157 administration.
- Nerve regeneration: A smaller but growing body of research has examined BPC-157 in models of peripheral nerve transection, reporting effects on axonal regrowth and functional recovery of innervated muscle.
Research Context: BPC-157 and Combination Protocols
Because BPC-157's research profile centres on angiogenesis and general tissue repair rather than any single injury type, it is frequently studied alongside other repair-oriented peptides in combination protocols β most commonly TB-500, whose actin-binding mechanism is complementary rather than overlapping. For a detailed look at this combination and the research rationale behind stacking the two compounds, see our BPC-157 and TB-500 research overview, and for a direct mechanistic comparison of the two peptides individually, see our BPC-157 vs TB-500 article.
Conclusion
BPC-157's combination of gastric-derived stability, apparent low toxicity across studied dose ranges, and activity across angiogenic, gastrointestinal, musculoskeletal, and neural repair models has made it one of the most widely referenced peptides in tissue-repair research literature. While the precise receptor-level mechanism remains an active area of investigation, the convergence of preclinical findings across independent research groups and tissue types continues to support its use as a research tool for studying wound healing and regenerative pathways. Malaysian researchers can find sourcing information in our guide on how to buy BPC-157 in Malaysia.
References
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Current Pharmaceutical Design. 2018;24(18):1990β2001.
- Chang CH, Tsai WC, Lin MS, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and angiogenesis." Journal of Applied Physiology. 2011;110(3):774β780.
- Sikiric P, Seiwerth S, Brcic L, et al. "Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator." Current Pharmaceutical Design. 2010;16(10):1224β1234.
- Vukojevic J, Vrdoljak B, Milavic M, et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regeneration Research. 2020;15(11):1943β1944.